You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Panitumumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

Stanford UniversityPhase 1/Phase 2
University of Wisconsin, MadisonPhase 2
Doris Duke Charitable FoundationPhase 2

See all panitumumab clinical trials

Recent Litigation for panitumumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Illumina, Inc.2020-12-02
Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.2013-10-08

See all panitumumab litigation

PTAB Litigation
GEMoaB Monoclonals GmbH2019-12-20
Forty Seven, Inc.2018-01-08

See all panitumumab litigation

Pharmacology for panitumumab
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for panitumumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Amgen Fremont Inc. (Fremont, CA) 2017-05-05 RX company
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Abgenix, Inc. (Fremont, CA) 2039-02-26 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for panitumumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4 Finland   Start Trial
411 Luxembourg   Start Trial 91411, EXPIRES: 20221203
C0022 France   Start Trial PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE IN FRANCE: EU/1/07/423/001 DU 20071203; REGISTRATION NO/DATE AT EEC: EU/1/07/423/001 DU 20071203
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.